Safety of 6000 Intravitreal Dexamethasone Implants

Written by: Katherine E. Talcott, MD Rajesh B, Zarranz-Ventura J, Fung AT et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2019 April 30. [Epub ahead of print] Corticosteroids, including the intravitreal dexamethasone implant, are used to treat macular edema from multiple etiologies. Clinical trials have revealed an increase in IOP and cataract […]

Non-supine Positioning after Macular Hole Surgery

Written by: Katherine E. Talcott, MD Lindtjorn B, Krohn J Austeng D et al. Nonsupine positioning after macular hole surgery: a prospective multicenter study. Ophthalmol Retina. 2019 May;3(5):388-92. Macular hole (MH) surgical repair typically involves the release of tangential traction on the retina by lifting the hyaloid, removal of the internal limiting membrane, epiretinal membrane, […]

Efficacy of topical timolol eye drops for the treatment of diabetic macular edema

Written by: Prethy Rao, MD Falavarjani K.G., Hadi Y., Habibi A., Anvari P., Modarres M., Parvaresh M.M.,Jafari S. & Alemzadeh S.A. Ophthalmol Retina. 2019 Jun;3(6):538-539 We live in an exciting time in retina with new pathway drugs being rolled into clinical trials and markets—from TIE2 receptors, DARPins, smaller VEGF antibody fragments (conbercerpt, brolicizumab) etc—for both macular […]

Macular Hole Hydrodissection for Persistent, Chronic, and Large Macular Holes

Written by: Maxwell S. Stem, MD Felfeli T, Mandelcorn ED. MACULAR HOLE HYDRODISSECTION: Surgical Technique for the Treatment of Persistent, Chronic, and Large Macular Holes. Retina. 2019;39(4):743-752. While the vast majority of full thickness macular holes (MH) close with standard vitrectomy surgery, peeling of the internal limiting membrane (ILM), and gas tamponade, there exists a […]

PIVOT: Pneumatic Retinopexy vs. Vitrectomy for Primary RRD

Written by: Maxwell S. Stem, MD Hillier RJ, Felfeli T, Berger AR, et al. The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT). Ophthalmology. 2019;126(4):531-539. The optimal management of a primary, uncomplicated rhegmatogenous retinal detachment (RRD) is a matter of some debate among vitreoretinal surgeons.  Recently, Hillier […]

Anti-VEGF Therapy and Associated Risk of Serious Cardiovascular Events

Written by: Judy J. Chen, MD Dalvin LA, Starr MR, AbouChehade JE, et al. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Risk of Stroke, Myocardial Infarction, and Death in Patients with Exudative Age-Related Macular Degeneration. JAMA Ophthalmol. 2019;137(5):483-490. Ever since intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents became the mainstay of […]